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INTRODUCTION 
After more than two decades of escalating morbidity and mortality 
stemming from the opioid epidemic in the United States, early signs 
suggest that specific mitigating interventions are taking hold to lessen 
deleterious public health impacts.  Declared public health emergencies at 
every level of government have led to legal reforms to monitor the crises 
and infuse essential resources.1  Extensive public education campaigns 
targeting health care workers and patients have significantly raised risk 
awareness.2  Unscrupulous doctors and entities operating pain 
management clinics (“pill mills”) have been prosecuted or disbanded.3  
National and regional lawsuits against pharmaceutical manufacturers, 
distributors, and retailers (among others) may lead to mass settlements 
and greater corporate accountability.4  Even as new forms of fentanyl, 
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 1.   Lawrence O. Gostin, James G. Hodge, Jr. & Sarah A. Noe, Reframing the Opioid 
Epidemic as a National Emergency, 318 JAMA 1539, 1539–1540 (2017), 
https://jamanetwork.com/journals/jama/fullarticle/2652445. 
 2.   See CTRS. FOR DISEASE CONTROL & PREVENTION, ADDRESSING THE PRESCRIPTION 
OPIOID CRISIS: CDC RX AWARENESS CAMPAIGN OVERVIEW (2017), https://www.cdc.gov/ 
rxawareness/pdf/Overview-Rx-Awareness-Resources.pdf [https://perma.cc/FY9N-B6T9].; Raising 
Awareness to Prevent Prescription Opioid Overdoses, CDC: PUB. HEALTH MATTERS BLOG (April 
30, 2018), https://blogs.cdc.gov/publichealthmatters/2018/04/rxawareness/ [https://perma.cc/ 
WC9W-SQJT]. 
 3.   See, e.g., Former Pill Mill Doctor Gets 157 Years for Drug Trafficking, AP NEWS (July 
31, 2018), https://www.apnews.com/c0de86998f184e24b3e4c2cc64123ebd [https://perma.cc/Q3WJ-
4GYF].  
 4.   See, e.g., id.; Del Quentin Wilber, Two Italians, Five Others, Charged in Deadly ‘Pill 
Mill’ Painkiller Scheme, WALL ST. J. (Jan. 19, 2018, 4:18 PM), https://www.wsj.com/articles/two-
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heroin, and other illicit opioids are surfacing through foreign channels,5 
significant curbs on prescribing practices of lawful opioid medications 
are helping to wean Americans off these highly-addictive drugs.6 
Despite these efforts, the original genesis for considerable opioid 
uptake in the U.S. remains.  Each year 30% of U.S. adults suffer from 
chronic or intermittent pain,7 or what has become known as the “fifth 
vital sign.”8  The rise of prescription opioids emanates in part from a 
national push to improve palliative care especially among insured 
patients with the capacity to pay for them.9  Completely eliminating 
patient access to prescription opioids is not an option.  Despite profound 
risks of addiction, prescription opioids work well.  Yet, public health 
interventions to curb opioids consequentially mean fewer patients are 
gaining regular access to opioids to control their pain.10  Multiple other 
pain treatments are either less potent (e.g., ibuprofen),11 more expensive 
                                                          
italians-five-others-charged-in-deadly-pill-mill-painkiller-scheme-1516396707 
[https://perma.cc/FPC4-C62Q]. 
 5.   See SEAN O’CONNOR, U.S.-CHINA ECON. & SEC. REVIEW COMM’N, FENTANYL: CHINA’S 
DEADLY EXPORT TO THE UNITED STATES 3 (2017), https://www.uscc.gov/ 
sites/default/files/Research/USCC%20Staff%20Report_Fentanyl-China’s%20Deadly%20Export%2 
0to%20the%20United%20States020117.pdf [https://perma.cc/F9EJ-ZP6U]. 
 6.   Abby Goodnough, As Opioid Prescriptions Fall, Prescriptions for Drugs to Treat 
Addiction Rise, N.Y. TIMES (Apr. 19, 2018), https://www.nytimes.com/2018/04/19/health/opioid-
prescriptions-addiction.html. 
 7.   See Catherine B. Johannes et al., The Prevalence of Chronic Pain in United States Adults: 
Results of an Internet-Based Survey, 11 J. PAIN 1230, 1230, 1234 (2010). 
 8.   Robert Heimer, Kathryn Hawk & Sten H. Vermund, Countering the Prevailing Narrative 
About the Causes of the US Opioid Crisis, 5 LANCET PSYCHIATRY 543, 543 (2018). 
 9.   See Dora H. Lin et al., Prescription Drug Coverage for Treatment of Low Back Pain 
Among US Medicaid, Medicare Advantage, and Commercial Insurers, JAMA NETWORK OPEN, June 
2018, at 10 (noting that drug coverage of health insurance plans impacts drug utilization and health 
outcomes and finding that existing insurance plans lack comprehensive strategies to prevent opioid 
misuse). 
 10.   Stephanie Armour, Opioid Crackdown Has Patients Struggling to Get Their Meds, WALL 
ST. J. (Apr. 26, 2018, 8:00 AM), https://www.wsj.com/articles/opioid-crackdown-has-patients-
struggling-to-get-their-meds-1524744001. 
 11.  See, e.g., Shayna Zelcer et al., Selective Potentiation of Opioid Analgesia by Nonsteroidal 
Anti-Inflammatory Drugs, 1040 BRAIN RES. 151, 151 (2005) (“NSAIDs have limited use in the 
management of moderate to severe pain due to a ceiling effect on their analgesic activity. . . . Opiate 
agonists, on the other hand, are powerful analgesics with no ceiling effects, but their utility is limited 
by adverse side effects.”).  Despite the difference in potency, emerging research suggests opioids 
and NSAIDs may have similar, but limited, clinical utility in chronic pain management.  See, e.g., 
Gustavo C. Machado et al., Non-Steroidal Anti-Inflammatory Drugs for Spinal Pain: A Systematic 
Review and Meta-Analysis, 76 ANNALS RHEUMATIC DISEASES 1269, 1269–78 (2017); see also 
NAT’L ACADS. OF SCIS., ENG’G, & MED., PAIN MANAGEMENT AND THE OPIOID EPIDEMIC: 
BALANCING SOCIETAL AND INDIVIDUAL BENEFITS AND RISKS OF PRESCRIPTION OPIOID USE 53–54 
(“[E]vidence exists to support the use of opioids for the treatment of some acute and subacute pain, 
[but] evidence to support their use to treat chronic pain is very limited.”). 
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(e.g., physical therapy),12 or still under development (e.g., tanezumab).13 
Another primary alternative to treat Americans’ pains is emerging: 
marijuana.14  Like opioids, marijuana and its varied derivatives have 
grown exponentially since first being authorized for medical use in 
California in 1996.15  Even though federal authorities still disapprove the 
drug for any purpose, thirty-three states and the District of Columbia 
now allow medical marijuana16 for a range of conditions, including 
palliative care.17  Despite thin proof of efficacy for treating many 
conditions, multiple states are pushing medical marijuana as a suitable 
substitute for prescription opioids to address pain as well as opioid-
related use disorders.18 
Critical issues of public health law and policy arise from the 
displacement of opioid drugs in favor of medical marijuana.  While these 
two classes of drugs are similarly intended to manage pain, their legality 
and public health impacts are highly divergent and subject to public 
misperceptions of their safety and effective use.19  Promoting marijuana 
over opioids is risky given substantial uncertainties over short- and long-
term impacts of its widespread use.20  Even as the nation slowly exits the 
                                                          
 12.   Mark Bishop, Physical Therapy Could Lower Need for Opioids, but Lack of Money and 
Time are Hurdles, THECONVERSATION.COM (June 22, 2018, 6:30 AM), 
http://theconversation.com/physical-therapy-could-lower-need-for-opioids-but-lack-of-money-and-
time-are-hurdles-92169 [https://perma.cc/KST3-3TJJ]. 
 13.   Brian Gormley, The Heated Quest for Opioid Alternatives, WALL ST. J. (May 25, 2018, 
10:36 AM), https://www.wsj.com/articles/the-heated-quest-for-opioid-alternatives-1527258997. 
 14.   See generally NAT’L ACADS. OF SCIS., ENG’G, & MED., THE HEALTH EFFECTS OF 
CANNABIS AND CANNABINOIDS: THE CURRENT STATE OF EVIDENCE AND RECOMMENDATIONS FOR 
RESEARCH (2017). 
 15.   Lawrence O. Gostin, James G. Hodge, Jr. & Sarah A. Wetter, Enforcing Federal Drug 
Laws in States Where Medical Marijuana Is Lawful, 319 JAMA 1435, 1435 (2018). 
 16.   The Network for Public Health Law, SURVEY: MEDICAL MARIJUANA PROGRAMS (2019), 
https://www.networkforphl.org/resources_collection/2017/07/17/486/survey_medical_marijuana_pr
ograms (last visited Mar. 3, 2019) [https://perma.cc/LZ4U-8W4D]. 
 17.   Billie Winegard et al., The Who, What, Where, When, Why and How of Medical Marijuana 
in Pediatric Palliative Care (FR416), 53 J. PAIN SYMPTOM MGMT. 356, 356 (2017). 
 18.   Christine Vestal, Can Marijuana Ease the Opioid Epidemic?, HUFFINGTON POST (Feb. 21, 
2017, 10:19 AM), https://www.huffingtonpost.com/entry/can-marijuana-ease-the-opioid-
epidemic_us_58ac598be4b0417c4066c2c8 [https://perma.cc/NQ6Z-NUHN]. 
 19.   See Anuj Shah et al., Impact of Medical Marijuana Legalization on Opioid Use, Chronic 
Opioid Use, and High-Risk Opioid Use, J. GEN. INTERNAL MED., Jan. 25, 2019, at 1–2, 6, 
https://link.springer.com/article/10.1007%2Fs11606-018-4782-2#citeas (noting that medical 
marijuana is publicly perceived as safe and may modestly reduce opioid use, but must be researched 
further to determine its health benefits in light of potential risks for increased mental health 
prevalence and marijuana misuse).  
 20.   See e.g., Gostin, Hodge & Wetter, supra note 15, at 1436 (“[L]imited funding and 
restrictive access to uniformly high-quality cannabis have sharply curtailed longitudinal studies” on 
medicinal marijuana). 
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long tunnel of the opioid crises, it may be heading into a fog of 
extensive, additional public health repercussions. 
I. SHIFTING EPIDEMIOLOGY AND LEGAL RESPONSES TO THE OPIOID 
EPIDEMIC 
Americans’ modern addiction to opioids of all types began in the 
1990s with the over-prescribing of new and lawful opioid drugs largely 
to treat their short- or long-term pain.21  Pushed by major pharmaceutical 
companies as a viable alternative to less effective pain treatments, 
prescription opioids became commonplace.22  With their rise came 
stealthy public health impacts.  The same qualities of prescription 
opioids that render them effective in mediating pain responses in the 
brain23 can also facilitate addiction.24  Relaxed oversight of opioid 
prescribing coupled with an under-appreciation of their addictive 
properties have inflated prescription practices, driven massive rates of 
addiction, and led to substantial morbidity and mortality from 
prescription opioid abuses and overdoses.25  Nearly 220,000 Americans 
have died from their misuse of prescription opioids over the last two 
decades.26  Almost 200,000 more have perished in the same period from 
illicit opioid abuses triggered in part by their initial addiction to 
prescription opioids.27 
                                                          
 21.   Keith Humphreys, Avoiding Globalisation of the Prescription Opioid Epidemic, 390 
LANCET 437, 437–38 (2017).   
 22.   See id. at 438. 
 23.   Pharmacologically, opioids bind to the μ-, κ-, and δ- opioid receptors of the brain, which 
are known to mediate pain, stress, and mood.  See generally Emmanuel Darcq & Brigitte Lina 
Kieffer, Opioid Receptors: Drivers to Addiction?, 19 NATURE REVIEWS NEUROSCIENCE 499 (2018). 
 24.   Nora D. Volkow & A. Thomas McLellan, Opioid Abuse in Chronic Pain—Misconceptions 
and Mitigation Strategies, 374 NEW ENG. J.  MED. 1253, 1254 (2016). 
 25.   See generally Laxmaiah Manchikanti et al., Therapeutic Use, Abuse, and Nonmedical Use 
of Opioids: A Ten-Year Perspective, 13 PAIN PHYSICIAN 401 (2010). 
 26.   CDC reports over 200,000 deaths from prescription opioids (natural and semisynthetic 
opioids, and methadone) between 1999 and 2016.  Puja Seth et al., Quantifying the Epidemic of 
Prescription Opioid Overdose Deaths, 108 AM. J. PUB. HEALTH 500, 501 (2018).  For 2017, CDC 
predicts that 18,382 additional deaths resulted from prescription opioids (natural and semisynthetic 
opioids, and methadone).  Vital Statistics Rapid Release: Provisional Drug Overdose Data, CDC 
[hereinafter Drug Overdose Data], https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm (last 
updated Jan. 16, 2019) [https://perma.cc/FEZ2-MJ23].  Prescription opioids caused about 46 deaths 
in the U.S. per day in 2017.  Opioid Data Analysis and Resources, CDC, https://www.cdc.gov/ 
drugoverdose/data/analysis.html (last updated Dec. 19, 2018) [https://perma.cc/7A3H-2YWZ].  
 27.   From 1999 to 2016, 85,090 deaths resulted from heroin and 64,685 deaths resulted from 
synthetic opioids, with mortality rates for synthetic opioids and heroin increasing exponentially.  
HOLLY HEDEGAARD, MARGARET WARNER & ARIALDI M. MINIÑO, CTRS. FOR DISEASE CONTROL & 
PREVENTION, DRUG OVERDOSE DEATHS IN THE UNITED STATES, 1999–2016, 4 & n.2 (2017), 
https://www.cdc.gov/nchs/data/databriefs/db294.pdf [https://perma.cc/3PFT-YTJ9].  For 2017, CDC 
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Preventable deaths due to prescription opioids are predicated on a 
reversal of historic pain management practices.  For years American 
medical professionals were fearful of overprescribing narcotic 
medications for chronic pain.28  Their reluctance to adequately treat 
patients’ pain generated ethical arguments focused on patient autonomy 
and diminished quality of life.29  Beginning in the 1980s, select 
researchers suggested that opioids could be prescribed safely with only 
minimal risks to patients of developing substance use disorders.30  By the 
late 1990’s, the American Medical Association31 and the American Pain 
Society32 were advocating for greater recognition and assessment of pain 
in the clinic.  Purdue Pharma released OxyContin in 1996 with an 
aggressive marketing and physician education campaign.33  The federal 
                                                          
predicts that 29,710 additional deaths resulted from synthetic opioids and 15,990 resulted from 
heroin.  Drug Overdose Data, supra note 26.  Forthcoming data for 2018 may sharply inflate these 
figures. 
 28.   Marcia L. Meldrum, The Ongoing Opioid Prescription Epidemic: Historical Context, 106 
AM. J. PUB. HEALTH 1365, 1365 (2016).  
 29.   See Diane E. Hoffmann & Anita J. Tarzian, Achieving the Right Balance in Oversight of 
Physician Opioid Prescribing for Pain: The Role of State Medical Boards, 31 J.L. MED. & ETHICS 
21, 21–23 (2003). 
 30.   See e.g., R. K. Portenoy & K. M. Foley, Chronic Use of Opioid Analgesics in Non-
Malignant Pain: Report of 38 Cases, 25 PAIN 171 (1986); Jane Porter & Hershel Jick, Addiction 
Rare in Patients Treated with Narcotics, 302 NEW ENG. J. MED. 123 (1980); Ronald M. Kanner & 
Kathleen M. Foley, Patterns of Narcotic Drug Use in a Cancer Pain Clinic, 362 ANNALS N.Y. 
ACAD. SCI. 161 (1981).  Though later criticized for their scant empirical groundings, the studies have 
been widely cited for the proposition that opioids present minimal addiction risks.  Pamela T.M. 
Leung et al., A 1980 Letter on the Risk of Opioid Addiction, 376 NEW ENG. J.  MED. 2194, 2194–95 
(2017); D. Andrew Tompkins et al., Providing Chronic Pain Management in the “Fifth Vital Sign” 
Era: Historical and Treatment Perspectives on a Modern-Day Medical Dilemma, 173 DRUG & 
ALCOHOL DEPENDENCE S11, S17 (2017). 
 31.   See, e.g., Art Derse, The Emergency Physician and End-of-Life Care, AMA J. ETHICS 
(Apr. 2001), https://journalofethics.ama-assn.org/article/emergency-physician-and-end-life-care/ 
2001-04 [https://perma.cc/3YY3-XVZW]. 
 32.   See, e.g., Mitchell B. Max et al., Quality Improvement Guidelines for the Treatment of 
Acute Pain and Cancer Pain, 274 JAMA 1874 (1995); Debra B. Gordon et al., American Pain 
Society Recommendations for Improving the Quality of Acute and Cancer Pain Management: 
American Pain Society Quality of Care Task Force, 165 ARCHIVES INTERNAL MED. 1574 (2005). 
The World Health Organization began recommending opioids for cancer pain in 1986.  WORLD 
HEALTH ORG., CANCER PAIN RELIEF (1986), http://apps.who.int/iris/bitstream/handle/10665/43 
944/9241561009_eng.pdf [https://perma.cc/4G59-9NPF]. 
 33.   GOV’T ACCOUNTABILITY OFFICE, PRESCRIPTION DRUGS: OXYCONTIN ABUSE AND 
DIVERSION AND EFFORTS TO ADDRESS THE PROBLEM 1–4 (2003), https://www.gao.gov/ 
new.items/d04110.pdf [https://perma.cc/X5M7-NCFN]; Theodore J. Cicero et al., Trends in Abuse 
of OxyContin® and Other Opioid Analgesics in the United States: 2002-2004, 6 J. PAIN 662, 662 
(2005).  Regulators in the U.S. permitted the labelling of OxyContin to indicate that addiction was 
uncommon when used appropriately.  Art Van Zee, The Promotion and Marketing of OxyContin: 
Commercial Triumph, Public Health Tragedy, 99 AM. J. PUB. HEALTH 221, 223 (2009).  Details 
from ongoing litigation suggests that Purdue may have known about the potential for abuse in 
opioids shortly after OxyContin was introduced, but still continued its campaign.  Barry Meier, 
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Department of Veterans Affairs (VA) adopted “Pain as 5th Vital Sign” in 
1999, requiring quantitative assessments of pain for all patients.34  By 
2001, the Joint Commission on Accreditation of Healthcare 
Organizations implemented new standards requiring practitioners at 
accredited hospitals to more fully evaluate and treat pain.35 
From 1997 to 2007 opioid prescriptions swelled 700% with an 
accompanying rise in mortality.36  Millions of other patients were 
accessing prescription opioids in greater doses and quantities.  The 
median size of each opioid prescription more than doubled from 2000 to 
2010.37  At the apex of the epidemic (see Figure 1 below), sixty-two 
million opioid prescriptions were filled in the final quarter of 2012 
alone.38  In 2015, 38% of Americans used prescription opioids for pain.39  
Prescription opioid-related deaths nearly quadrupled from 1999 to 
2012.40 
 
                                                          
Origins of an Epidemic: Purdue Pharma Knew Its Opioids Were Widely Abused, N.Y. TIMES (May 
29, 2018), https://www.nytimes.com/2018/05/29/health/purdue-opioids-oxycontin.html. 
 34.   See DEP’T OF VETERANS AFFAIRS, PAIN AS THE 5TH VITAL SIGN TOOLKIT 7 (2000), 
https://www.va.gov/PAINMANAGEMENT/docs/Pain_As_the_5th_Vital_Sign_Toolkit.pdf 
[https://perma.cc/5YTE-YJXV]; Richard A. Mularski et al., Measuring Pain as the 5th Vital Sign 
Does Not Improve Quality of Pain Management, 21 J. GEN. INTERN MED. 607 (2006).  
 35.   Donald M. Phillips, JCAHO Pain Management Standards Are Unveiled, 284 JAMA 428 
(2000); see also Tompkins et al., supra note 30, at S13. 
 36.   Edward W. Boyer, Management of Opioid Analgesic Overdose, 367 NEW ENG. J.  MED. 
146, 146 (2012); see also Christos A. Grigoras et al., Correlation of Opioid Mortality with 
Prescriptions and Social Determinants: A Cross-sectional Study of Medicare Enrollees, 78 DRUGS 
111 (2018) (finding a correlation between opioid prescription rates and mortality rates).  “[T]he 
prevalence of patient-reported pain . . . remained stable [during this time, but] the proportion of visits 
where patients reported severe pain increased . . . .”  Hsien-Yen Chang et al., Prevalence and 
Treatment of Pain in EDs in the United States, 2000 to 2010, 32 AM. J. EMERGENCY MED. 421, 426 
(2014). Prescribing rates did vary by specialty.  Benjamin Levy et al., Trends in Opioid Analgesic–
Prescribing Rates by Specialty, U.S., 2007–2012, 49 AM. J. PREVENTATIVE MED. 409, 409 (2015). 
 37.   FOOD & DRUG ADMIN., FDA ANALYSIS OF LONG-TERM TRENDS IN PRESCRIPTION OPIOID 
ANALGESIC PRODUCTS 1 (2018), https://www.fda.gov/downloads/AboutFDA/ReportsManuals 
Forms/%20Reports/UCM598899.pdf [https://perma.cc/6X7S-DGMU]. 
 38.   Richard C. Dart et al., Trends in Opioid Analgesic Abuse and Mortality in the United 
States, 372 NEW ENG. J. MED. 241, 243 (2015). 
 39.   Beth Han et al., Prescription Opioid Use, Misuse, and Use Disorders in U.S. Adults: 2015 
National Survey on Drug Use and Health, 167 ANNALS INTERNAL MED. 293, 293–301 (2017).  
Prescription opioids were distributed for relatively minor injuries.  For example, 25% of emergency 
department patients with sprained ankles received an opioid prescription in 2015.  M. Kit Delgado et 
al., National Variation in Opioid Prescribing and Risk of Prolonged Use for Opioid-Naive Patients 
Treated in the Emergency Department for Ankle Sprains, 72 ANNALS EMERGENCY MED. 389, 389 
(2018). 
 40.   MARGARET WARNER ET AL., TRENDS IN DRUG-POISONING DEATHS INVOLVING OPIOID 
ANALGESICS AND HEROIN: UNITED STATES, 1999–2012, 5 (2014), https://www.cdc.gov 
/nchs/data/hestat/drug_poisoning/drug_poisoning_deaths_1999-2012.pdf [https://perma.cc/PBG4-
6S3W]. 
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Figure 1. U.S. Opioid Prescribing Rates41 
 
Significant rises in mortality alarmed public health, law enforcement, 
and safety officials at all levels of government.42  In 2014, the federal 
Drug Enforcement Administration (DEA) elevated hydrocodone 
combination opioids from Schedule III to II via the Controlled 
Substances Act (CSA),43 which sharply decreased prescription rates of 
these drugs.44  The Centers for Disease Control and Prevention (CDC) 
                                                          
 41.   Information for this figure is adapted from publicly available CDC data published online.  
U.S. Opioid Prescribing Rate Maps, CDC, https://www.cdc.gov/drugoverdose/maps/rxrate-
maps.html (last updated Oct. 3, 2018) [https://perma.cc/KHG8-JAPZ]. 
 42.   MARGARET WARNER ET AL., INCREASE IN FATAL POISONINGS INVOLVING OPIOID 
ANALGESICS IN THE UNITED STATES, 1999-2006, 1, 4–5 (2009), https://www.cdc.gov/ 
nchs/products/databriefs/db22.htm [https://perma.cc/F6JK-UN22] (“Several government agencies 
are taking action on opioid analgesic-related poisonings including CDC, DEA, the National Institute 
on Drug Abuse, the Office of National Drug Control Policy, the Substance Abuse and Mental Health 
Services Administration, and the U.S. Food and Drug Administration.”); Barry Meier, Move to 
Restrict Pain Killers Puts Onus on Doctors, N.Y. TIMES (July 28, 2010), https://www.nytimes.com/ 
2010/07/29/business/29pain.html; Sabrina Tavernise, Ohio County Losing Its Young to Painkillers’ 
Grip, N.Y. TIMES (Apr. 19, 2011), https://www.nytimes.com/2011/04/20/us/20drugs.html.  
 43.   Schedules of Controlled Substances: Rescheduling of Hydrocodone Combination Products 
From Schedule III to Schedule II, 79 Fed. Reg. 49, 661 (Aug. 22, 2014) (codified at 21 C.F.R. 
§ 1308).   
 44.   Christopher M. Jones et al., Effect of US Drug Enforcement Administration’s Rescheduling 
of Hydrocodone Combination Analgesic Products on Opioid Analgesic Prescribing, 176 JAMA 
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published national prescribing guidelines for opioids in 2016, 
recommending lower dosing regimens, risk assessments for all patients, 
and properly-timed termination of opioid therapy.45  In 2017, the Food 
and Drug Administration (FDA) requested Endo Pharmaceuticals to 
completely withdraw a high-risk prescription opioid from the market.46  
FDA further required drug companies to educate providers on safely 
prescribing opioids and considering alternatives.47  The Department of 
Justice (DOJ) began to crack down on unscrupulous pill mills, 
prosecuting hundreds of providers.48  On October 26, 2017, the 
Department of Health and Human Services (HHS) declared the opioid 
epidemic a national public health emergency,49 which it has renewed 
three times for ninety-day periods.50 
States have also responded extensively to rising prescription rates.51  
                                                          
INTERNAL MED. 399, 401–02 (2016).  
 45.   Deborah Dowell et al., CDC Guideline for Prescribing Opioids for Chronic Pain — 
United States, 2016, 65 MMWR RECOMMENDATIONS REP. 1, 1–49 (2016), 
https://www.cdc.gov/mmwr/volumes/65/rr/rr6501e1.htm [https://perma.cc/S2WP-5SBQ]. 
 46.   Press Release, Food & Drug Admin., FDA Requests Removal of Opana for Risks Related 
to Abuse (June 8, 2017), https://www.fda.gov/newsevents/newsroom/pressannouncements/ 
ucm562401.htm [https://perma.cc/3YF9-GX77].  The company later complied with FDA’s request.  
Ed Silverman, Endo Gives in to FDA Demand and Agrees to Yank Its Opioid Painkiller, STAT (July 
6, 2017) https://www.statnews.com/pharmalot/2017/07/06/endo-opana-fda-opioid/ [https://perma.cc/ 
BKQ5-6GLD].  Some evidence suggests FDA withdrawal of another opioid, Propoxyphene, from 
the market in 2010 and the introduction of forms of opioids that were resistant to abuse led to 
decreases in prescribing rates.  Marc R. Larochelle et al., Rates of Opioid Dispensing and Overdose 
After Introduction of Abuse-Deterrent Extended-Release Oxycodone and Withdrawal of 
Propoxyphene, 175 JAMA INTERNAL MED. 978, 985 (2015). 
 47.   Opioid Analgesic Risk Evaluation and Mitigation Strategy (REMS), FDA, 
https://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm163647.htm (last updated Dec. 
17, 2018). 
 48.   Press Release, Dep’t of Justice, National Health Care Fraud Takedown Results in Charges 
Against 601 Individuals Responsible for Over $2 Billion in Fraud Losses (June 28, 2018),  
https://www.justice.gov/opa/pr/national-health-care-fraud-takedown-results-charges-against-601-
individuals-responsible-over [https://perma.cc/EK54-2GKB]. 
 49.   President Donald J. Trump Is Taking Action on Drug Addiction and the Opioid Crisis, 
WHITEHOUSE.GOV (Oct. 26, 2017), https://www.whitehouse.gov/briefings-statements/president-
donald-j-trump-taking-action-drug-addiction-opioid-crisis/ [https://perma.cc/7YNE-4JAR]. 
 50.   Eric D. Hargan, Renewal of Determination that a Public Health Emergency Exists, 
PHE.GOV (Jan. 19, 2018), https://www.phe.gov/emergency/news/healthactions/phe/Pages/opioid-
24Jan2018.aspx [https://perma.cc/TRC9-3K7D]; Alex M. Azar II, Renewal of Determination that a 
Public Health Emergency Exists, PHE.GOV (Apr. 24, 2018), https://www.phe.gov/emergency/news/ 
healthactions/phe/Pages/opioid-20Apr2018.aspx [https://perma.cc/R33D-TUTN]; Alex M. Azar II, 
Renewal of Determination that a Public Health Emergency Exists, PHE.GOV (July 19, 2018), 
https://www.phe.gov/emergency/news/healthactions/phe/Pages/opioid-19July2018.aspx 
[https://perma.cc/6KAT-33RK]. 
 51.   See NAT’L GOVERNORS ASS’N, FINDING SOLUTIONS TO THE PRESCRIPTION OPIOID AND 
HEROIN CRISIS (2016), https://classic.nga.org/files/live/sites/NGA/files/pdf/2016/1607NGAOpioid 
RoadMap.pdf [https://perma.cc/WU3E-DYKU].  Local, tribal, and industry moves have also 
accompanied state actions.  See, e.g., Hearing on “Local Responses and Resources to Curtail the 
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Since 2000, the number of states with a prescription drug monitoring 
program (PDMP) rose from seventeen to forty-nine.52  Twenty-nine 
states require prescribers to review PDMP data related to specific 
patients prior to prescribing an opioid.53  CDC attributes new PDMP 
standards to helping tamp down prescription opioid rates.54  By 2010, 
states began setting extensive registration requirements for pain 
management clinics.55  Multiple states overhauled their opioid 
prescribing guidelines56 and capped supplies for first-time 
prescriptions.57  By 2015, twenty-three states legally required physician 
continuing education in controlled substance prescribing or pain 
management.58  Like the federal government, eight states (AK, AZ, FL, 
MA, MD, PA, SC, VA) have used their emergency powers to bolster 
their abilities and funding to respond to opioid-related public health 
harms.59 
Multi-leveled legal responses and public understanding have 
contributed to lower prescription rates beginning in 2013.60  As per 
                                                          
Opioid Epidemic” Before the Subcomm. on Health Care, Benefits and Administrative Rules, 115th 
Cong. (2018). 
 52.   PRESCRIPTION DRUG MONITORING PROGRAM TRAINING & TECH. ASSISTANCE CTR., 
HISTORY OF PRESCRIPTION DRUG MONITORING PROGRAMS 1, 5 (2018), http://www.pdmpassist.org/ 
pdf/PDMP_admin/TAG_History_PDMPs_final_20180314.pdf [https://perma.cc/3S5X-SBH4]. See 
generally Rebecca L. Haffajee et al., Mandatory Use of Prescription Drug Monitoring Programs, 
313 JAMA 891, 891 (2015). 
 53.   Brian Suffoletto et al., The Effect of a Statewide Mandatory Prescription Drug Monitoring 
Program on Opioid Prescribing by Emergency Medicine Providers Across 15 Hospitals in a Single 
Health System, 19 J. PAIN 430, 431 (2018).  
 54.   Opioid Painkiller Prescribing Infographic, CDC, https://www.cdc.gov/vitalsigns/opioid-
prescribing/infographic.html [https://perma.cc/9K7M-SJWA] (last reviewed July 1, 2014). 
 55.   See, e.g., Lainie Rutkow et al., Effect of Florida’s Prescription Drug Monitoring Program 
and Pill Mill Laws on Opioid Prescribing and Use, 175 JAMA INTERNAL MED. 1642 (2015); 
Tatyana Lyapustina et al., Effect of a “Pill Mill” Law on Opioid Prescribing and Utilization: The 
Case of Texas, 159 DRUG & ALCOHOL DEPENDENCE 190 (2016). 
 56.   See generally COREY S. DAVIS, THE NETWORK FOR PUB. HEALTH LAW, STATE-BY-STATE 
SUMMARY OF OPIOID PRESCRIBING REGULATIONS AND GUIDELINES (2017), https://www.azdhs.gov/ 
documents/prevention/womens-childrens-health/injury-prevention/opioid-prevention/appendix-b-
state-by-state-summary.pdf [https://perma.cc/GMG5-HN4W] (appearing as Appendix B in the 
Arizona Department of Health Service’s 50 State Review on Opioid Policy). 
 57.   Prescribing Policies: States Confront Opioid Overdose Epidemic, NCSL (Oct. 31, 2018), 
http://www.ncsl.org/research/health/prescribing-policies-states-confront-opioid-overdose-
epidemic.aspx [https://perma.cc/7LPA-QBBL].  
 58.   See Corey S. Davis & Derek Carr, Physician Continuing Education to Reduce Opioid 
Misuse, Abuse, and Overdose: Many Opportunities, Few Requirements, 163 DRUG & ALCOHOL 
DEPENDENCE 100, 102 (2016).  
 59.   JAMES G. HODGE, JR. & CHELSEA GULINSON, THE NETWORK FOR PUB. HEALTH LAW, 
OPIOID PUBLIC HEALTH EMERGENCIES (2019), https://www.networkforphl.org/_asset/g8ymnu/ 
Opioid-Public-Health-Emergencies-3-1-19.pdf [https://perma.cc/QHB9-NPP2 ]. 
 60.   CDC recognizes state-level policies and increased awareness of risks from opioids are 
likely drivers of the decreases.  Anne Schuchat et al., New Data on Opioid Use and Prescribing in 
 
888 KANSAS LAW REVIEW Vol. 67 
Figure 1, after peaking between 2010 and 2012, prescription rates 
decreased by over 13% by 201561 and remained in decline through 
2017.62  The VA reports that 99% of their hospital systems decreased 
their prescribing rates between 2012 and 2018, some by upwards of 
70%.63  Purdue Pharma released a full page advertisement in the New 
York Times on August 1, 2018 stating “[w]e are acutely aware of the 
public health risks opioid analgesics can create, even when taken as 
prescribed” and detailing their responses including “provid[ing] 
funding . . . to distribute the overdose rescue drug naloxone.”64  One 
national poll determined that 46% of Americans not prescribed opioids in 
2016 expressed concerns about the use of prescription opioids, up from 
30% in 2011.65  Substantial efforts to reduce prescribing rates of opioids, 
                                                          
the United States, 318 JAMA 425, 425 (2017); State Successes, CDC, https://www.cdc.gov/ 
drugoverdose/policy/successes.html (last updated Oct. 5, 2017) [https://perma.cc/49Z2-SAD7].  
Prescription rates vary by county, with higher rates observed in Appalachia, the South, and rural 
regions in the West.  See U.S. Opioid Prescribing Rate Maps, CDC, https://www.cdc.gov/ 
drugoverdose/maps/rxrate-maps.html (last updated Oct. 3, 2018) [https://perma.cc/49N8-VGH5]; 
Lyndsey A. Rolheiser et al., Opioid Prescribing Rates by Congressional Districts, United States, 
2016, 108 AM. J. PUB. HEALTH 1214 (2018). 
 61.   Gery P. Guy Jr. et al., Vital Signs: Changes in Opioid Prescribing in the United States, 
2006–2015, 66 MORBIDITY & MORTALITY WKLY. REP. 697, 698–99 (2017) (though the prescription 
rate remained three times greater than the rate in 1999). Contra Molly Moore Jeffery et al., Trends in 
Opioid Use in Commercially Insured and Medicare Advantage Populations in 2007-16: 
Retrospective Cohort Study, BMJ, Aug. 1, 2018, at 1, https://doi.org/10.1136/bmj.k2833 (finding no 
significant change in opioid prescription rates in a study of 48 million insured individuals). 
 62.   IQVIA INST., MEDICINE USE AND SPENDING IN THE U.S. 2 (2018), 
https://www.iqvia.com/institute/reports/medicine-use-and-spending-in-the-us-review-of-2017-
outlook-to-2022 [https://perma.cc/PQ3W-8NV7].  Further data shows falling prescription rates in 
different insured populations.  See, e.g., Ashley C. Bradford et al., Association Between US State 
Medical Cannabis Laws and Opioid Prescribing in the Medicare Part D Population, 178 JAMA 
INTERNAL MED. 667 (2018); BLUE CROSS BLUE SHIELD, THE OPIOID EPIDEMIC IN AMERICA 2–11 
(2018), https://www.bcbs.com/sites/default/files/file-attachments/health-of-america-report/HoA_ 
Opioid_Epidemic_Report.pdf [https://perma.cc/3JK6-4YR4 ]. 
 63.   See Dep’t of Veterans Affairs, Department of Veterans Affairs Opioid Prescribing Data, 
VAOPENDATA.CARTO.COM (2018), https://vaopendata.carto.com/builder/74f45d51-cc44-4d29-
b852-c1a2b39f303d/embed (last visited Feb. 10, 2019). 
 64.   Purdue Pharma, We Make Prescription Opioids. And We Want to Limit Their Use, N.Y. 
TIMES, Aug. 1, 2018, at A5; see also Purdue Pharma, We Make Prescription Opioids. And We Want 
to Limit Their Use, WALL ST. J. (July 23, 2018), https://www.washingtonpost.com/brand-
studio/wp/2018/07/19/we-make-prescription-opioids-and-we-want-to-limit-their-
use/?utm_term=.ac6f8760de61.  The advertisement was also published as an open letter on the 
company’s website on July 20, 2018.  We Make Prescription Opioids. And We Want to Limit Their 
Use, PURDUE PHARMA, http://www.purduepharma.com/corporate-social-responsibilities/ongoing-
efforts-to-help-address-the-opioid-crisis/open-letter/ (last visited Aug. 2, 2018).  The advertisement 
came in the context of escalating litigation against opioid manufacturers.  See Rebecca L. Haffajee & 
Michelle M. Mello, Drug Companies’ Liability for the Opioid Epidemic, 377 NEW ENG. J. MED. 
2301 (2017). 
 65.   TRUVEN & NPR, HEALTH POLL: NARCOTIC PAINKILLERS 6 (2017), 
http://truvenhealth.com/Portals/0/NPR-Truven-Health-Poll/TRU_17400_0117_NPRSurvey 
_Narcotic.pdf (margin of error = ± 1.8%, survey of 3,000 people) [https://perma.cc/FD39-LCRJ]. 
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however, have generated significant costs via substance abuse 
treatments66 and concerns among physicians and patients regarding 
access to effective palliative treatments for patients with intermittent or 
chronic pain.67 
II. ESCALATION OF MEDICAL MARIJUANA 
Quelling prescription opioid use is about saving lives, not denying 
access to palliative care.  Consequently, public health officials, medical 
practitioners, and patients are seeking opioid alternatives to address 
pain.68  General anti-inflammatory medications (e.g. ibuprofen) are cheap 
but considerably less potent.69  Physical therapy is often prohibitively 
expensive or cumbersome for some patients to complete.70  Some 
providers are using therapeutics outside of manufacturer 
recommendations (e.g. spinal corticosteroid injections) with associated 
adverse consequences.71  Additional pain treatment options (e.g. nerve 
growth factor inhibitors, slow-release post-surgical anesthetics) are in 
development but currently unapproved.72  The imminent need for 
alternative palliative treatments is leading many patients and providers to 
consider marijuana as a viable option.73 
While medicinal use of cannabis date back thousands of years,74 the 
modern era of medical marijuana blossomed in 1996 with the passage of 
California’s Compassionate Use Act.75  Favorable policies toward 
                                                          
 66.   Cynthia Cox et al., A Look at How the Opioid Crisis Has Affected People with Employer 
Coverage, PETERSON-KAISER HEALTH SYS. TRACKER (Apr. 5, 2018), 
https://www.healthsystemtracker.org/brief/a-look-at-how-the-opioid-crisis-has-affected-people-with-
employer-coverage/#item-start [https://perma.cc/AYS8-TAY9].  
 67.   Richard S. Larson & Halena M. Gazelka, Should the Government Limit a Physician’s 
Ability to Treat Patients With Opioids?, WALL ST. J. (June 24, 2018, 10:05 PM), 
https://www.wsj.com/articles/should-the-government-limit-a-physicians-ability-to-treat-patients-
with-opioids-1529892300. 
 68.   Brian Gormley, The Heated Quest for Opioid Alternatives, WALL ST. J. (May 29, 2018, 
10:36 AM), https://www.wsj.com/articles/the-heated-quest-for-opioid-alternatives-1527258997. 
 69.   See supra note 11 and accompanying text. 
 70.   Bishop, supra note 12. 
 71.   Injection of corticosteroids, like Depo-Medrol, into the spine sometimes leads to 
“blindness, stroke, paralysis, and death.”  Sheila Kaplan, After Doctors Cut Their Opioids, Patients 
Turn to a Risky Treatment for Back Pain, N.Y. TIMES, (July 31, 2018), https://www.nytimes.com/ 
2018/07/31/health/opioids-spinal-injections.html. 
 72.   Gormley, supra note 68.  
 73.   See generally, NAT’L ACADS. OF SCIS., ENG’G, & MED., supra note 14. 
 74.   J. Michael Bostwick, Blurred Boundaries: The Therapeutics and Politics of Medical 
Marijuana, 87 MAYO CLINIC PROC. 172, 174 (2012). 
 75.   CAL. HEALTH & SAFETY CODE § 11362.5(a) (West 2007).  See Jessica Berch, Reefer 
Madness: How Non-Legalizing States Can Revamp Dram Shop Laws to Protect Themselves from 
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marijuana consumption reflect bipartisan public support.  One 2018 poll 
suggested 93% of Americans approve medicinal marijuana.76  As 
illustrated in Figure 2, marijuana use in the U.S. has risen over the last 
decade across all age groups (especially persons aged 18-29 years). 
 
Figure 2. Marijuana Use (1984-2015)77 
 
As of August 1, 2018, thirty states and the District of Columbia 
(which collectively comprise 78% of the U.S. population78) legally allow 
medical cannabis (see Figure 3 below), subject to multiple limitations.  
                                                          
Marijuana Spillover from Their Legalizing Neighbors, 58 B.C. L. REV. 863, 864 (2017). 
 76.   See PETER A. BROWN & PAT SMITH, QUINNIPIAC UNIV. POLL, U.S. VOTERS BELIEVE 
COMEY MORE THAN TRUMP, QUINNIPIAC UNIVERSITY NATIONAL POLL FINDS; SUPPORT FOR 
MARIJUANA HITS NEW HIGH 2 (2018), https://poll.qu.edu/images/polling/us/us04262018_ 
ufcq23.pdf/ [https://perma.cc/82GK-YJQE]. 
 77.   Data for this figure were condensed and reformatted from William C. Kerr et al., Trends 
and Age, Period and Cohort Effects for Marijuana Use Prevalence in the 1984-2015 US National 
Alcohol Surveys, 113 ADDICTION 473 (2018). 
 78.   See State Population Totals and Components of Change: 2010-2018, U.S. CENSUS 
BUREAU, https://www.census.gov/data/datasets/time-series/demo/popest/2010s-state-total.html#par_ 
textimage_500989927 (last updated Dec. 6, 2018). 
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In most states, medical marijuana may be authorized only to treat 
specific ailments.  Laws vary as to whether patients may cultivate 
cannabis at home or are limited to accessing it through licensed 
dispensaries.79  Ten jurisdictions also permit recreational uses of 
marijuana, essentially allowing persons to acquire and use marijuana for 
any purpose.80 
Figure 3. Medical and Recreational Marijuana Use Laws81 
 
 
Evolution of state marijuana policies contravene federal marijuana 
prohibitions.82  As a CSA Schedule I drug, marijuana (like heroin) is 
viewed as having a high potential for abuse and no safe or effective 
medical uses.83  This classification is highly controversial across states 
                                                          
 79.   Marijuana Deep Dive, NCSL, http://www.ncsl.org/bookstore/state-legislatures-
magazine/marijuana-deep-dive.aspx (last visited Feb. 25, 2019) [https://perma.cc/MLX7-KA3B]. 
 80.   Jeremy Berke & Skye Gould, This Map Shows Every US State Where Pot is Legal, BUS. 
INSIDER (Jan. 4, 2019, 12:49 PM), https://www.businessinsider.com/legal-marijuana-states-2018-1; 
see also Berch, supra note 75, at 864–66. 
 81.   Figure is based on data from The Network for Public Health Law, supra note 16. 
 82.   21 U.S.C. § 812 (2012 & Supp. 5). 
 83.   Unsuccessful petitions to change marijuana’s classification date back to 1972.  In August 
2016, the Drug Enforcement Administration (DEA) affirmed marijuana’s Schedule I classification.  
Schedule I classifications also significantly restrict research.  See Diane Hoffmann et al., Will The 
FDA’s Approval Of Epidiolex Lead To Rescheduling Marijuana?, HEALTH AFF. BLOG (July 12, 
2018), https://www.healthaffairs.org/do/10.1377/hblog20180709.904289/full/ [https://perma.cc/ 
LPH2-6MEX].  
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and even within the federal sector.84  Cannabidiol (CBD), an active non-
hallucinogen extract from marijuana, for example, has known medicinal 
properties that have long been recognized by federal and state health 
authorities.85  On June 25, 2018, FDA approved Epidiolex, an epilepsy 
drug containing CBD.86 
In 2005, the U.S. Supreme Court ruled that DOJ can enforce federal 
drug laws against purely intrastate commercialization of medicinal 
marijuana.87  Yet, by 2013, following considerable negotiations under 
President Obama’s administration, DOJ released guidance to limit 
federal enforcement against state medical marijuana programs.88  This 
guidance was abruptly rescinded on January 4, 2018, by Attorney 
General Jeff Sessions.89  He threatened to prosecute marijuana 
manufacturers, distributors, and practitioners even as U.S. Attorneys 
largely refused to do so in states where marijuana use is legal.90  On June 
7, 2018, Senators Elizabeth Warren (D-MA) and Cory Gardner (R-CO) 
introduced the Strengthening the Tenth Amendment Through Entrusting 
States (STATES) Act to expressly exempt cannabis use in legalized 
states from federal prosecution.91  President Trump expressed support for 
the bill.92  Some states and localities have opted to reduce charges93 or 
                                                          
 84.   See generally Rebecca L. Haffajee et al., Behind Schedule—Reconciling Federal and State 
Marijuana Policy, 379 NEW ENG. J. MED. 501 (2018). 
 85.   Alice Mead, The Legal Status of Cannabis (Marijuana) and Cannabidiol (CBD) Under 
U.S. Law, 70 EPILEPSY & BEHAV. 288, 288–89 (2017). 
 86.   For the first time, FDA approved an extract of the marijuana plant for medical use.  
Acknowledgement of a viable medical use of marijuana may support its CSA reclassification.  
Hoffmann et al, supra note 83.  
 87.   Gonzales v. Raich, 545 U.S. 1, 9 (2005). 
 88.   Memorandum from James M. Cole, Deputy Attorney General, on Guidance Regarding 
Marijuana Enforcement to All United States Attorneys (Feb. 14, 2014), 
https://dfi.wa.gov/documents/banks/dept-of-justice-memo.pdf [https://perma.cc/R7N6-TB7E]. 
 89.   Memorandum from Jeffrey B. Sessions, III, Attorney General, on Marijuana Enforcement 
to All United States Attorneys (Jan. 4, 2018) [hereinafter Sessions Memo], 
https://www.justice.gov/opa/press-release/file/1022196/download [https://perma.cc/QB57-JJVM].  
The Trump administration has since clarified that, with limited resources to prosecute “small 
marijuana cases,” its primary focus remains on drug gangs and larger conspiracies.  Sadie Gurman, 
Sessions: US Prosecutors Won’t Take on Small-Time Pot Cases, AP NEWS (Mar. 10, 2018), 
https://apnews.com/5b27da207202466f90a08ae87614eaea [https://perma.cc/T2FA-GG3P]. 
 90.   Sessions Memo, supra note 89. 
 91.   Strengthening the Tenth Amendment Through Entrusting States Act, S.3032, 115th Cong. 
(2018).  The same day, Rep. David Joyce (R-OH) and Rep. Earl Blumenauer (D-OR) introduced 
H.R. 6043, a companion House Bill.  Neither bill made it out of committee. See also PETER A. 
BROWN & PAT SMITH, supra note 76 (finding 74% of Americans would support a bill protecting 
states that have legalized medicinal or recreational marijuana from federal prosecution). 
 92.   Eileen Sullivan, Trump Says He’s Likely to Back Marijuana Bill, in Apparent Break With 
Sessions, N.Y. TIMES (June 8, 2018), https://www.nytimes.com/2018/06/08/us/politics/trump-
marijuana-bill-states.html. 
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excuse prior convictions for mere possession or use of marijuana.94 
Despite its convoluted legal status, marijuana is known as an 
effective treatment for symptoms of conditions including HIV/AIDS and 
cancer.95  Some studies suggest that marijuana is a viable treatment for 
symptoms of multiple sclerosis, Tourette syndrome, anxiety, epilepsy, 
and posttraumatic stress disorder.96  In 2017, the National Academies 
found “substantial evidence” that marijuana (and its subcomponents) can 
also help alleviate chronic pain.97  However, efficacy of marijuana as a 
palliative drug is not fully proven.  While opioids are effective “pain 
killers,” marijuana is more like a “pain distracter.”98  Still, Americans 
appear poised to substitute marijuana in place of opioids.  One study 
suggests that states permitting medical cannabis (especially jurisdictions 
with dispensaries) saw significantly lower daily opioid prescriptions 
compared to states that do not permit marijuana.99 
Ultimately, the viability of medical marijuana as an opioid 
alternative may turn on its safety, although a lack of reliable public 
health surveillance and research may discount potential short- and long-
term risks of marijuana use.  Marijuana may not contribute substantially 
to overdose-related deaths,100 but available research has uncovered 
detrimental harms to users.  Well-known side effects of acute cannabis 
use include “impairment in the cognitive domains of learning, memory, 
and attention,”101 as well as sleepiness, confusion, and tachycardia (rapid 
                                                          
 93.   See, e.g., Steven M. Fulop & Jacob V. Hudnut, Pressing Pause on Pot Convictions, N.Y. 
TIMES (July 30, 2018), https://www.nytimes.com/2018/07/29/opinion/pot-decriminalization-jersey-
city.html. 
 94.   See, e.g., Timothy Williams & Thomas Fuller, San Francisco Will Clear Thousands of 
Marijuana Convictions, N.Y. TIMES (Jan. 31, 2018), https://www.nytimes.com/2018/01/31/ 
us/california-marijuana-san-francisco.html.  
 95.   See NAT’L ACADS. OF SCIS., ENG’G, & MED., supra note 14, at 85–97.   
 96.   Id. at 99–104, 118–29. 
 97.   Id. at 87–90.   
 98.   Joseph Stromberg, Marijuana Isn’t a Pain Killer—It’s a Pain Distracter, 
SMITHSONIAN.COM (Dec. 20, 2012), https://www.smithsonianmag.com/science-nature/marijuana-
isnt-a-pain-killerits-a-pain-distracter-169786068/ [https://perma.cc/3W95-N7ZH]. Unlike opioids, 
which bind to opioid receptors to block pain, cannabis does not block pain through the same 
neurological mechanisms.  See generally Katia Befort, Interactions of the Opioid and Cannabinoid 
Systems in Reward: Insights from Knockout Studies, FRONTIERS PHARMACOLOGY, Feb. 2015, at 1, 
https://www.frontiersin.org/articles/10.3389/fphar.2015.00006/pdf [https://perma.cc/KCX6-AK89].  
One study shows that using THC only increases the individual’s ability to tolerate pain, with no 
decrease in actual pain levels.  Michael C. Lee et al., Amygdala Activity Contributes to the 
Dissociative Effect of Cannabis on Pain Perception, 154 PAIN 124 (2013). 
 99.   Bradford et. al, supra note 62, at 667. 
 100.   Richard A. Friedman, Marijuana Can Save Lives, N.Y. TIMES (Feb. 8, 2018), 
https://www.nytimes.com/2018/02/08/opinion/marijuana-opiates-jeff-sessions.html. 
 101.   NAT’L ACADS. OF SCIS., ENG’G, & MED., supra note 14, at 18. 
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heart rate).102  Effects of long-term use, however, could be far more 
precarious.  There is substantial evidence103 that effects of prolonged 
marijuana use may include increased risks of respiratory disease 
complications (e.g., for chronic bronchitis), vehicular collisions, and 
schizophrenia (as well as other forms of psychosis),104 with moderate 
evidence105 of dependence and substance use disorders related to alcohol, 
tobacco, and other illicit drugs.106 
Impacts of marijuana use among youth may be especially profound.  
Studies demonstrate that early-onset marijuana use in youth and young 
adults detrimentally impairs cognitive function and IQ score.107  Even 
though many states require package warning labels against marijuana use 
among pregnant and breast-feeding women,108 prenatal cannabis use is 
on the rise.109  THC can cross the placental barrier, adversely impacting 
“fetal and postnatal brain development [and] neuronal connectivity.”110 
III. TRANSITIONING FROM OPIOIDS TO MARIJUANA 
National and state public health efforts to diminish prescription 
opioids share the immediate objective of reducing preventable deaths 
stemming from opioid addictions.  Whether these laudable policies are 
properly motivated in the interests of the public’s health is beyond 
debate.  Nor is it a matter of denying patients access to available and 
effective palliative care alternatives.  The most pertinent question is 
                                                          
 102.   Mohamed Ben Amar, Cannabinoids in Medicine: A Review of Their Therapeutic 
Potential, 105 J. ETHNOPHARMACOLOGY 1, 10–13 (2006). 
 103.  For evidence to be “substantial” there must be “several supportive findings from good-
quality studies with very few or no credible opposing findings.”  NAT’L ACADS. OF SCIS., ENG’G, & 
MED., supra note 14, at 7.  This requires that a “firm conclusion can be made, but minor limitations, 
including chance, bias, and confounding factors, cannot be ruled out with reasonable confidence.”  
Id. 
 104.   Id. at 16–19. 
 105.   For evidence to be “moderate” there must be several supportive findings from good- to 
fair-quality studies with very few or no credible opposing findings.”  Id. at 8.  This requires that a 
“general conclusion can be made, but limitations, including chance, bias, and confounding factors, 
cannot be ruled out with reasonable confidence.”  Id. 
 106.   Arpana Agrawal et al., A Twin Study of Early Cannabis Use and Subsequent Use and 
Abuse/Dependence of Other Illicit Drugs, 34 PSYCHOL. MED. 1227, 1227 (2004). 
 107.   E.g., Lisa Buchy et al., Evaluating the Relationship Between Cannabis Use and IQ in 
Youth and Young Adults at Clinical High Risk of Psychosis, 230 PSYCHIATRY RES. 878 (2015). 
 108.   See, e.g., ALASKA ADMIN. CODE tit. 3, § 306.345(b)(3)(E) (2019).  
 109.   Lauren M. Jansson et al., Perinatal Marijuana Use and the Developing Child, 320 JAMA 
545, 545 (2018). 
 110.   Id.  The endocannabinoid system develops very early in a fetus’ life (around 14-weeks).  
Id.  Tetrahydrocannabinol (THC) is a prominent cannabinoid found in the cannabis plant with 
psychoactive properties.  Id. 
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whether anti-opioid policies may lead to other public health 
repercussions impacting the same or different populations affected by 
widespread prescription opioid use.  Specifically, is the substitution of 
marijuana as a viable alternative to prescription opioids an effective, 
long-term public health strategy,111 or just another wrong turn on the road 
to treating Americans’ physical and mental pains? 
These issues are percolating against the backdrop of states’ latest 
directives in the battle over widespread opioid uses.  Over two million 
Americans with known opioid use disorders (OUDs) are receiving 
specialized treatment interventions;112 millions more likely need 
treatment now (or will soon) as opioid reduction strategies progress.113  
Multiple state policymakers propose marijuana not just as a viable 
palliative care option, but also as a potential drug to help ameliorate the 
symptoms of opioid withdrawal.114  Under this view, marijuana is not 
merely an alternative to treating Americans’ underlying sources of pain, 
but also for their newfound medical needs stemming from opioid 
withdrawals. 
To address the underlying issue of chronic pain, several states have 
added chronic or intractable pain as qualifying conditions for medical 
cannabis.115  In 2018, three states (NJ, NY, PA) explicitly added opioid 
                                                          
 111.   See generally Esther K. Choo et al., Opioids Out, Cannabis In: Negotiating the Unknowns 
in Patient Care for Chronic Pain, 316 JAMA 1763 (2016); Kevin P. Hill & Andrew J. Saxon, 
Commentary, The Role of Cannabis Legalization in the Opioid Crisis, 178 JAMA INTERNAL MED. 
679 (2018). 
 112.   REBECCA AHRNSBRAK ET AL., SUBSTANCE ABUSE & MENTAL HEALTH SERV. ADMIN. 
(SAMHSA), KEY SUBSTANCE USE AND MENTAL HEALTH INDICATORS IN THE UNITED STATES: 
RESULTS FROM THE 2016 NATIONAL SURVEY ON DRUG USE AND HEALTH 2 (2017), 
https://store.samhsa.gov/system/files/sma17-5044.pdf [https://perma.cc/W4A7-L2VT].  SAMHSA 
reports that only 11% of Americans needing substance use disorder treatment receive specialized 
interventions.  Id.  Similar numbers were reported in 2015.  See JONAKI BOSE ET AL., SUBSTANCE 
ABUSE & MENTAL HEALTH SERV. ADMIN., KEY SUBSTANCE USE AND MENTAL HEALTH 
INDICATORS IN THE UNITED STATES: RESULTS FROM THE 2015 NATIONAL SURVEY ON DRUG USE 
AND HEALTH 2 (2016), https://www.samhsa.gov/data/sites/default/files/NSDUH-FFR1-2015/ 
NSDUH-FFR1-2015/NSDUH-FFR1-2015.pdf [https://perma.cc/D3LR-X5HC]. 
 113.   OUDs precipitate in 8–12% of patients prescribed opioids.  Kevin E. Vowles et al., Rates 
of Opioid Misuse, Abuse, and Addiction in Chronic Pain: A Systematic Review and Data Synthesis, 
156 PAIN 569, 573 (2015). 
 114.   These assertions are often buttressed by recent correlative studies showing decreased 
opioid overdose-related death rates in states that legalized marijuana.  See, e.g., Marcus A. 
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use disorder to their indications for obtaining medical marijuana.116  In 
January 2018, New Jersey Governor Phil Murphy prompted the state’s 
Department of Health to review its medical cannabis program.  In an 
Executive Order, he intimated that increased access to medical marijuana 
would make patients “less likely to turn to potentially more harmful and 
less medically appropriate drugs such as opioids.”117  Two months later, 
the Department announced that “chronic pain conditions that are related 
to musculoskeletal disorders” would qualify patients for medical 
marijuana.118  Health officials later confirmed that this category includes 
OUDs arising from the treatment of chronic pain with opioids.119 
In May 2018, the Pennsylvania Department of Health moved to 
provide access to medical marijuana for OUDs and authorized university 
research on medicinal uses for cannabis.120  Its rule explicitly denotes 
opioid use disorder as a qualifying condition for marijuana,121 whether or 
not the disorder resulted from traditional pain management.  However, 
justifying a prescription for medical marijuana still requires that 
“conventional therapeutic interventions [for opioid use disorder] are 
contraindicated or ineffective” or that cannabis is used in concert with 
another therapeutic.122  According to Pennsylvania’s Secretary of Health, 
Dr. Rachel Levine, while cannabis cannot replace established 
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BOSTON GLOBE (Nov. 5, 2018), https://www.bostonglobe.com/news/marijuana/2018/11/05/ohio-
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PROGRAM (Mar. 22, 2018), https://www.nj.gov/health/medicalmarijuana/documents/MMP_Final 
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interventions for opioid use disorder, the shift would “give physicians 
another tool for treatment of this devastating disease.”123 
On July 12, 2018, New York State approved even broader access to 
marijuana in responding to the opioid crisis.124  Its new rules signaled 
that marijuana may be a suitable substitute for “pain that degrades health 
and functional capability where the use of medical marijuana is an 
alternative to opioid use, provided that the precise underlying condition 
is expressly stated on the patient’s certification.”125  New York State 
added opioid use disorder as one condition to use medical cannabis so 
long as patients participate in a certified treatment program.126  
Essentially, marijuana may be given to patients suffering not only from 
OUDs, but also any other condition for which an opioid may have been 
prescribed.  Moreover, New York’s rule does not mandate exhaustion of 
other treatment options prior to allowing medical marijuana.127  The New 
York Department of Health simultaneously recommended that the State 
authorize regulated recreational uses of marijuana as well in part to 
address the opioid epidemic.128 
To the extent that states expand their medical marijuana programs to 
address pain and treat OUDs,129 marijuana is more than a potential 
substitution for opioids.  It becomes a proposed partial solution to the 
prescription opioid epidemic.  These state policies, however, are 
                                                          
 123.   PA. OFFICE OF THE GOVERNOR, supra note 120. 
 124.   New York State Department of Health Announces Opioid Replacement Now a Qualifying 
Condition for Medical Marijuana, N.Y. STATE DEP’T OF HEALTH (July 12, 2018), 
https://www.health.ny.gov/press/releases/2018/2018-07-12_opioid_replacement.htm 
[https://perma.cc/9AZN-DF4A]. 
 125.   N.Y. COMP. CODES R. & REGS. tit. 10, § 1004.2(a)(8)(xiii) (2018). 
 126.   Id. § 1004.2(a)(9)(vii). 
 127.   Id. § 1004. 
 128.   N.Y. DEP’T OF HEALTH, ASSESSMENT OF THE POTENTIAL IMPACT OF REGULATED 
MARIJUANA IN NEW YORK STATE 6 (2018), https://www.health.ny.gov/regulations/ 
regulated_marijuana/docs/marijuana_legalization_impact_assessment.pdf [https://perma.cc/U59B-
NK4Z] (“Medical marijuana has added another option for pain relief which may reduce initial 
prescribing of opioids and assist individuals who currently use opioids to reduce or stop use.  
Legalization may ease access to marijuana for pain management.”). 
 129.   Two other states, Connecticut and Hawaii, recently considered similar proposals.  
Connecticut’s Department of Consumer Protection voted against the prospective rules. Press 
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embroiled in legal and public health controversies.130  From the federal 
perspective, the irony of using an illicit drug, marijuana, to remedy 
harms of lawful drugs, prescription opioids, is not likely lost on DOJ.  
New York’s proposed policy to recreationalize marijuana specifically to 
address opioid morbidity and mortality could be especially egregious.  
Although federal laws and policies on the legality of marijuana are 
shifting to better reflect public sentiments and states’ permissive 
approaches,131 they do not currently align.  Resulting federal 
prosecutions, sanctions, and prohibitions may still follow. 
One such prohibition relates to insurance coverage.  Since marijuana 
remains an illicit, Schedule I drug, federally-funded health insurers (e.g. 
Medicare, Medicaid, VA, Indian Health Service) and substance abuse 
providers cannot pay for or reimburse costs of medical marijuana uses.132  
Consequently, limited insurance coverage for medical cannabis can make 
it more expensive to treat pain than cheaper prescription opioids covered 
by insurers.133  Use of marijuana to address OUDs is essentially banned 
from federal reimbursement.  Providers and patients seeking medicinal 
uses of marijuana may thus have to rely on many patients’ capacities to 
self-fund the medications.  As with many other medical injustices, 
patients of lower socioeconomic statuses (or living in places not 
authorizing medical marijuana) may lack access to refined medical 
marijuana products.  Patients turning to unregulated synthetic 
cannabinoids instead risk ingesting products laced with deadly synthetic 
opioids like fentanyl.134 
The dual policy premise that substituting marijuana for opioids 
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 131.   See Peter A. Brown, supra note 76. 
 132.   B. Jessie Hill, What is the Meaning of Health? Constitutional Implications of Defining 
“Medical Necessity” and “Essential Health Benefits” Under the Affordable Care Act, 38 AM. J. L. 
& MED. 445, 469 (2012) (“cannabis is not currently approved by the FDA, and therefore is not 
generally covered by insurers”); Emily Corwin, The High Cost of Medical Marijuana Causes Pain 
in Vermont, NPR (Jan. 11, 2018, 7:27 PM), https://www.npr.org/sections/health-shots/2018/01/ 
11/577411274/the-high-cost-of-medical-marijuana-causes-pain-in-vermont [https://perma.cc/9Q7B-
47QF] (“the federal government won’t allow states to cover medical marijuana with Medicaid 
dollars”); VA and Marijuana–What Veterans Need to Know,  U.S. DEP’T VETERANS AFF., 
https://www.publichealth.va.gov/marijuana.asp (last visited Feb. 10, 2019) [https://perma.cc/CL7V-
DF99] (“VA will not pay for medical marijuana prescriptions from any source.”). 
 133.   Corwin, supra note 132. 
 134.   See Scott Neuman, Dozens Overdose in Connecticut Park on Tainted Synthetic Marijuana, 
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provides an effective and failsafe way for Americans to simultaneously 
treat pain and derail drug misuse is challengeable.  One longitudinal 
study identified continued opioid use and lower self-efficacy regarding 
one’s ability to manage pain in patients using long-term cannabis.135  If 
these findings are further validated, marijuana may provide minimal or 
no effectiveness in permanently weaning chronic pain patients off 
opioids.  The National Academies found (1) moderate evidence of a 
correlation between cannabis use and developing substance use disorders 
and (2) limited evidence on how marijuana use affects patients’ use of 
other substances.136  These trends suggest that marijuana use may 
predispose individuals to substance use disorders and contraindicate the 
promotion of medical cannabis to stem OUDs.  Unfortunately, further 
research on the long-term clinical impacts of cannabis is confounded by 
federal regulatory and funding limitations.137 
From a public health point of view, transferring population health 
risks of one primary class of drugs (opioids) to another (marijuana) 
seems innocuous at first glance.  As noted, the goal of saving lives 
otherwise lost to opioids should dominate decision-making (although 
some may disagree on utilitarian grounds).  In the fervor to save tens of 
thousands of lives, however, is the potential to negatively impact the 
short- and long-term health of millions of Americans via known and 
unknown effects of marijuana use.138  As the epidemic wave of opioid-
related morbidity and mortality predictably lessens, resulting adverse 
effects of marijuana use, especially among younger Americans, could 
swell in the years ahead.  This might very well be a trade-off worth 
making if only public health impacts of long-term cannabis use across 
populations were better understood. 
CONCLUSION 
Exiting the long, horrid tunnel of deaths and morbidity tied to the 
twenty-plus year opioid epidemic, the forward view is promising.  
Affirmative interventions to stymie prescription opioids and their abuse 
are being undertaken.  Corporate accountability is unfolding.  Real 
changes in practitioner and patient understanding and behaviors are 
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emerging.  Still, the road ahead is cloudy.  Treating Americans’ pain 
remains a priority, but suitable opioid alternatives are few.  Marijuana 
emerges as an obvious choice of multiple state policy-makers.  It is 
relatively inexpensive, available lawfully in most states, comes in many 
forms, and is increasingly supported by the public for medicinal uses.  
However, greater uptake of marijuana, even purely for medicinal 
purposes, faces significant legal hurdles and an uphill climb concerning 
proof of efficacy to address pain or opioid use disorders.  Public health 
and safety risks of long-term marijuana use, especially among younger 
generations, represent more than a slight curve in the road.  With 
relatively little known under current surveillance and research, these 
hazards may constitute the next mountainous epidemic the nation must 
ascend. 
 
